Zevra Therapeutics, Inc. (ZVRA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 82.38M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 74.63M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82.38M | (m) | (m) | (m) | $74.63M | (m) |
| 2026-03-31 | $-5.43M | (m) | (m) | (m) | $78.85M | (m) |
| 2025-12-31 | $-62.94M | (m) | (m) | (m) | $77.62M | (m) |
| 2025-09-30 | $-87.67M | (m) | (m) | (m) | $73.39M | (m) |
| 2025-06-30 | $-119.12M | (m) | (m) | (m) | $72.66M | (m) |
| 2025-03-31 | $-71.88M | (m) | (m) | (m) | $64.48M | (m) |
| 2024-12-31 | $-87.00M | (m) | (m) | (m) | $54.87M | (m) |
| 2024-09-30 | $-86.74M | (m) | (m) | (m) | $53.40M | (m) |
| 2024-06-30 | $-74.80M | (m) | (m) | (m) | $43.01M | (m) |
| 2024-03-31 | $-57.26M | (m) | (m) | (m) | $37.02M | (m) |
| 2023-12-31 | $-49.60M | (m) | (m) | (m) | $34.31M | (m) |
| 2023-09-30 | $-44.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-35.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-53.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-42.51M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-36.09M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-31.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-1.09M | (m) | (m) | $10.98M | (m) | (m) |
| 2021-12-31 | $7.73M | (m) | (m) | $10.16M | (m) | (m) |
| 2021-09-30 | $7.36M | (m) | (m) | $10.41M | (m) | (m) |
| 2021-06-30 | $8.37M | (m) | (m) | $9.88M | (m) | (m) |
| 2021-03-31 | $5.13M | (m) | (m) | $8.98M | (m) | (m) |
| 2020-12-31 | $-5.61M | (m) | (m) | $8.84M | (m) | (m) |
| 2020-09-30 | $-6.80M | (m) | (m) | $8.25M | (m) | (m) |
| 2020-06-30 | $-2.36M | (m) | (m) | $10.16M | (m) | (m) |
| 2020-03-31 | $-12.74M | (m) | (m) | $13.01M | (m) | (m) |
| 2019-12-31 | $-20.34M | (m) | $10.00M | $19.41M | (m) | (m) |
| 2019-09-30 | $-25.20M | (m) | (m) | $23.25M | (m) | (m) |
| 2019-06-30 | $-46.39M | (m) | (m) | $32.97M | (m) | (m) |
| 2019-03-31 | $-52.50M | (m) | (m) | $38.65M | (m) | (m) |
| 2018-12-31 | $-55.90M | (m) | (m) | $41.76M | (m) | (m) |
| 2018-09-30 | $-54.78M | (m) | (m) | $40.99M | (m) | (m) |
| 2018-06-30 | $-46.44M | (m) | (m) | $33.95M | (m) | (m) |
| 2018-03-31 | $-40.76M | (m) | (m) | $28.12M | (m) | (m) |
| 2017-12-31 | $-33.37M | (m) | (m) | $20.59M | (m) | (m) |
| 2017-09-30 | $-36.05M | (m) | (m) | $23.02M | (m) | (m) |
| 2017-06-30 | $-36.84M | (m) | (m) | $21.01M | (m) | (m) |
| 2017-03-31 | $-37.89M | (m) | (m) | $21.35M | (m) | (m) |
| 2016-12-31 | $-37.48M | (m) | (m) | $20.47M | (m) | (m) |
| 2016-09-30 | $-33.93M | (m) | (m) | $17.23M | (m) | (m) |
| 2016-06-30 | $-30.01M | (m) | (m) | $17.27M | (m) | (m) |
| 2016-03-31 | $-26.69M | $0.00 | (m) | $15.05M | (m) | (m) |
| 2015-12-31 | $-22.81M | $0.00 | (m) | $13.93M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-16.44M | $0.00 | (m) | $11.92M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-4.72M | $0.00 | (m) | $3.37M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |